ZIMLABPharmaceuticals
Zim Laboratories Ltd — Cash Flow Statement
₹60.26
-0.45%
Zim Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.36 Cr | -57.65 Cr | 1.50 Cr | 33.98 Cr | — |
| Repayment Of Debt | -15.32 Cr | -12.93 Cr | -15.47 Cr | -29.93 Cr | — |
| Issuance Of Debt | 24.62 Cr | 28.15 Cr | 18.35 Cr | 27.07 Cr | — |
| Capital Expenditure | -40.80 Cr | -73.92 Cr | -36.67 Cr | -15.23 Cr | — |
| End Cash Position | 1.95 Cr | 9.60 Cr | 6.42 Cr | 3.42 Cr | — |
| Beginning Cash Position | 9.60 Cr | 6.42 Cr | 3.42 Cr | 1.39 Cr | — |
| Effect Of Exchange Rate Changes | 0.22 Cr | 0.38 Cr | 0.49 Cr | 0.36 Cr | — |
| Changes In Cash | -7.88 Cr | 2.80 Cr | 2.51 Cr | 1.66 Cr | — |
| Financing Cash Flow | -9.10 Cr | 59.53 Cr | 0.55 Cr | -32.97 Cr | — |
| Net Other Financing Charges | 0.06 Cr | 21.45 Cr | 0.06 Cr | 6.59 Cr | — |
| Interest Paid Cff | -12.30 Cr | -7.51 Cr | -5.53 Cr | -7.93 Cr | — |
| Cash Dividends Paid | -0.06 Cr | -0.05 Cr | -0.06 Cr | -0.17 Cr | — |
| Net Issuance Payments Of Debt | 6.78 Cr | 47.37 Cr | 8.47 Cr | -30.24 Cr | — |
| Net Short Term Debt Issuance | -2.53 Cr | 32.15 Cr | 5.59 Cr | -27.38 Cr | — |
| Net Long Term Debt Issuance | 9.30 Cr | 15.21 Cr | 2.88 Cr | -2.86 Cr | — |
| Long Term Debt Payments | -15.32 Cr | -12.93 Cr | -15.47 Cr | -29.93 Cr | — |
| Long Term Debt Issuance | 24.62 Cr | 28.15 Cr | 18.35 Cr | 27.07 Cr | — |
| Investing Cash Flow | -39.93 Cr | -73.01 Cr | -36.20 Cr | -14.57 Cr | — |
| Interest Received Cfi | 0.05 Cr | 0.04 Cr | 0.08 Cr | 0.19 Cr | — |
| Dividends Received Cfi | 75000.00 | 60000.00 | 60000.00 | 60000.00 | — |
| Net Investment Purchase And Sale | 0.09 Cr | 0.31 Cr | 0.36 Cr | 0.30 Cr | — |
| Sale Of Investment | 0.44 Cr | 0.60 Cr | 0.36 Cr | 0.30 Cr | — |
| Purchase Of Investment | -0.35 Cr | -0.28 Cr | 0.00 | — | — |
| Net PPE Purchase And Sale | -40.07 Cr | -73.38 Cr | -36.65 Cr | -15.07 Cr | — |
| Sale Of PPE | 0.73 Cr | 0.55 Cr | 0.02 Cr | 0.16 Cr | — |
| Purchase Of PPE | -40.80 Cr | -73.92 Cr | -36.67 Cr | -15.23 Cr | — |
| Operating Cash Flow | 41.15 Cr | 16.28 Cr | 38.17 Cr | 49.21 Cr | — |
| Taxes Refund Paid | 1.08 Cr | -2.58 Cr | -7.15 Cr | -0.43 Cr | — |
| Change In Working Capital | -10.36 Cr | -26.79 Cr | -12.19 Cr | 6.58 Cr | — |
| Change In Inventory | 3.73 Cr | 7.91 Cr | 21.58 Cr | -20.94 Cr | — |
| Change In Receivables | -14.10 Cr | -34.69 Cr | 2.69 Cr | -1.99 Cr | — |
| Other Non Cash Items | 11.16 Cr | 6.74 Cr | 5.33 Cr | 7.97 Cr | — |
| Stock Based Compensation | 1.35 Cr | 0.00 | — | — | 0.00 |
| Provisionand Write Offof Assets | -0.72 Cr | -0.17 Cr | 0.79 Cr | 0.00 | — |
| Depreciation And Amortization | 20.11 Cr | 15.95 Cr | 17.47 Cr | 16.03 Cr | — |
| Amortization Cash Flow | 1.86 Cr | 2.86 Cr | — | — | — |
| Depreciation | 18.26 Cr | 13.09 Cr | 17.47 Cr | 16.03 Cr | — |
| Pension And Employee Benefit Expense | -1.10 Cr | -4000.00 | -1.05 Cr | -1.01 Cr | — |
| Gain Loss On Investment Securities | -75000.00 | -60000.00 | -60000.00 | -60000.00 | — |
| Net Foreign Currency Exchange Gain Loss | -0.30 Cr | -1.14 Cr | -1.02 Cr | -0.98 Cr | — |
| Gain Loss On Sale Of PPE | -0.34 Cr | -0.47 Cr | -0.02 Cr | -0.06 Cr | — |
| Net Income From Continuing Operations | 18.01 Cr | 23.64 Cr | 35.35 Cr | 21.04 Cr | — |
| Issuance Of Capital Stock | — | 21.40 Cr | 0.00 | 0.00 | 0.06 Cr |
| Net Common Stock Issuance | — | 21.40 Cr | 0.00 | 0.00 | 0.06 Cr |
| Common Stock Issuance | — | 21.40 Cr | 0.00 | 0.00 | 0.06 Cr |
| Short Term Debt Issuance | — | 32.15 Cr | 5.59 Cr | — | — |
| Change In Payable | — | 7.91 Cr | -36.47 Cr | 29.51 Cr | 2.63 Cr |
| Net Other Investing Changes | — | — | 0.36 Cr | 0.30 Cr | 0.20 Cr |
| Net Business Purchase And Sale | — | — | — | — | 0.00 |
| Purchase Of Business | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zim Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.